Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Riemser Arzneimittel AG

www.riemser.com

Latest From Riemser Arzneimittel AG

Biopharma Dealmaking Quarterly Statistics, Q3 2012

Q3 2012 biopharma financing, at just over $3 billion, showed a 13% increase over Q2. Follow-on public offerings again were the most prevalent financing type, accounting for a third of these dollars. M&A volume was down to just over $7 billion, compared with Q2’s $35.9 billion and only two Q3 transactions topped the billion-dollar mark. Antibody alliances made up just over a quarter of the total $2.2 billion in deal volume, with 19 deals signed in the area.

BioPharmaceutical Deals

Deals Shaping The Medical Industry, October 2012

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device

Deals Of The Week: Allergan/Molecular Partners, Silence Therapeutics/MiReven, Pfizer/Mylan

The widely dispersed array of developmental therapies for conditions such as non-small cell lung cancer and type 2 diabetes begs the question of whether it would make more sense to have a biopharmaceutical industry based on solution-focused companies approaching a single problem from multiple angles.

BioPharmaceutical Deals

German Specialty Pharma Firm Riemser Arzneimittel Bought By AXA Private Equity

AXA Private Equity's acquisition of Riemser Arzneimittel is the third change of ownership in the European specialty pharmaceuticals and manufacturing sectors this month, with more likely to follow as buyout specialists seeks the right combination of companies for consolidation.

BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Riemser Arzneimittel AG
  • Senior Management
  • Michael Mehler , CEO
    Beatrice von Buchwaldt, CFO
    Michael Pister, Head, Bus. Dev. & Licensing
  • Contact Info
  • Riemser Arzneimittel AG
    Phone: (49) 3851-76-129
    An der Wiek 7
    Greifswald, Isle of Riems , 17493
    Germany
UsernamePublicRestriction

Register